Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and SurvivalDik J. Kwekkeboom, Eric P. Krenning, Wouter W. de Herder et al.|Journal of Clinical Oncology|2008Cited by 1.4k
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine TumorsTessa Brabander, Dik J. Kwekkeboom, Boen L.R. Kam et al.|Clinical Cancer Research|2017Cited by 604
Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumorsDik J. Kwekkeboom, Eric P. Krenning, Boen L.R. Kam et al.|Endocrine Related Cancer|2009Cited by 462
Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experienceRoelf Valkema, Eric P. Krenning, Marion de Jong et al.|Seminars in Nuclear Medicine|2002Cited by 433
Neuroendocrine TumorsUrsula Plöckinger, Marianne Pavel, Guido Rindi et al.|Gastrointestinal Oncology|2008Cited by 2